Home › Meningioma › Wisconsin
Meningioma clinical trials in Wisconsin
4 studies for Meningioma are looking for participants at sites in Wisconsin.
Cities in Wisconsin
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Duluth Clinic Ashland, Ashland
- Northwest Wisconsin Cancer Center, Ashland
- Aurora Cancer Care-Southern Lakes VLCC, Burlington
- and 27 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT02523014Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
- Medical College of Wisconsin, Milwaukee
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06955169A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- UW Carbone Cancer Center, Madison
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07428616Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Froedtert Medical College of Wisconsin, Milwaukee
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated May 14, 2026 · NCT05636618From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.